Regeneron Pharmaceuticals REGN announced that the FDA has approved extending dosing intervals of up to every 20 weeks for ...
Investor's Business Daily on MSN
Stock of the day in buy zone, leads industry despite supersmall market
The stock is one of only two in IBD's biotech group with highest-possible 99 Composite Ratings.
Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research on MSN
Will Regeneron (REGN) beat estimates again in its next earnings report?
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results